Analysts Hail Pearson's Return To Valeant As Patent Challenges From Allergan Looms

HFA Padded
Mark Melin
Published on
Updated on
Valeant 2 29 stock price

Patent challenges, restatement of earnings and lack of forward looking guidance are all greeting Michael Pearson, Valeant’s former Chairman and CEO, who is coming back to the firm today. Pearson’s job responsibilities are being clipped, with his chairman title being an oversight role at Valeant to be executed by Robert A. Ingram, a former executive of GlasxoSmithKline, the company announced over the weekend. Analysts encouraging on Pearson’s Valeant return but concerned about lack of financial guidance The meme among bank analysts regarding the return of Pearson was overwhelmingly supportive, but one issue was raised. JPMorgan called the coming home party…

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

Comments are closed.